About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Focus on Antidepressants and Atypical Antipsychotic Agents
Military clinical practice guidelines formerly recommended off-label atypical antipsychotic agents for treating traumatized war veterans. Although the guidelines have been revised, it may be too early to exclude these drugs in all cases.
News & Analysis
Battles Loom as Congress Aims to Pass a Major Bill by September 2012
The REMS programs produced by drug companies vary greatly, often making life difficult for pharmacists, mainly because so far, the FDA has not established a standard format. The companies also haven’t been too happy with the FDA’s unfocused administration of its REMS authority, which the agency admits needs to be clarified.
A Literature Review
Reviewing articles and abstracts published from January 1974 to May 2008, the authors found that increasing patient cost sharing was associated with declines in medication adherence, which in turn were related to poorer health outcomes.
Michael T. Eaddy, PharmD, PhD; Christopher L. Cook, PharmD, PhD; Ken O’Day, PhD, MPA; Steven P. Burch, PhD, RPh; and C. Ron Cantrell, PhD
Topics include extended-release niacin for lowering low-density lipoprotein-
cholesterol; vorapaxar for reducing acute coronary syndromes; the use of drug-eluting stents instead of balloon-eluting stents in patients at risk for bleeding; and the impact of free drugs versus copays on adherence to medications.
Matthew Grissinger, RPh, FASCP
Medicare wants to make sure that consultant pharmacists who work in long-term-care facilities have no conflicts of interest.
FDA approvals, drug indications, and updates
Ruxolitinib (Jakafi) for the treatment of myelofibrosis, aflibercept (Eylea) for patients with neovascular (wet) age-related macular degeneration; and cord blood (Hemacord) for stem-cell transplantation
Marvin M. Goldenberg, PhD, RPh, MS
A Serotonin Partial Agonist and Reuptake Inhibitor for the Treatment of Major Depressive Disorder
Vilazodone (Viibryd) for major depressive disorder
Martin Paspe Cruz, PharmD, CGP, BCPP